Alecnib 150 MG (Alectinib)

Basic Product Information of Alecnib 150 MG (Alectinib)

How Alecnib 150 MG (Alectinib) Works: Second-Generation ALK Tyrosine Kinase Inhibition Mechanism

Alectinib, the active ingredient in Alecnib 150 MG, is a second-generation, highly selective, oral anaplastic lymphoma kinase (ALK) and RET proto-oncogene tyrosine kinase inhibitor. Its primary molecular target is the EML4-ALK fusion oncoprotein and other ALK gene rearrangements, which together account for approximately 3 to 5% of non-small cell lung cancer (NSCLC) diagnoses and drive malignant cell proliferation, survival, and metastasis through constitutive ALK kinase activation. Under normal physiology, ALK mediates neuronal development and differentiation through ligand-dependent signaling. When chromosomal inversions or translocations fuse ALK to partner genes, most commonly EML4, the resulting fusion proteins become constitutively active kinases that continuously signal through downstream proliferative pathways, including RAS/ERK, PI3K/AKT, and JAK/STAT3, sustaining tumor growth without requiring normal regulatory input.

Alectinib’s decisive clinical advantage over first-generation ALK inhibitor crizotinib derives from two distinguishing molecular properties. First, alectinib maintains potent inhibitory activity against the broad spectrum of crizotinib-resistance ALK mutations that emerge in tumor cells after first-generation TKI therapy, including L1196M (the “gatekeeper” mutation that eliminates crizotinib’s binding hydrogen bond), C1156Y, F1174L, L1152R, and G1269A. These mutations reduce crizotinib binding affinity substantially but do not impair alectinib binding, enabling clinical responses after crizotinib failure. Second, alectinib achieves substantially superior CNS penetration compared with crizotinib, which is a P-glycoprotein (P-gp) efflux transporter substrate at the blood-brain barrier that severely limits crizotinib’s intracranial drug concentration. Alectinib is not a P-gp substrate at clinically relevant concentrations and therefore reaches therapeutically meaningful levels in brain parenchyma, providing direct intracranial tumor control. Oncologists building a comprehensive lung cancer treatment program can access Alecnib 150 MG alongside a full portfolio of ALK-pathway agents and precision oncology therapies through Mediaid Pharmacy’s oncology medicines catalog.

In the landmark ALEX trial (phase III, first-line, 303 patients), alectinib delivered a median PFS of 34.8 months versus 10.9 months for crizotinib (hazard ratio 0.43; 95% CI 0.32 to 0.58; p less than 0.001), a CNS objective response rate of 81% versus 50% for crizotinib in patients with measurable baseline CNS lesions, and a CNS progression rate of only 12% versus 45% for crizotinib at data maturity. The 5-year PFS rate was 19.0% for alectinib versus 0% for crizotinib, a difference that quantifies alectinib’s durable long-term tumor control advantage at the population level. In the ALESIA trial (phase III, Asian patients, first-line, 187 patients), alectinib produced a median PFS of not yet reached versus 11.1 months for crizotinib (hazard ratio 0.22; 95% CI 0.13 to 0.38), with a CNS ORR of 94.1% versus 28.6% for crizotinib in patients with baseline CNS disease, independently confirming first-line superiority across a racially distinct patient population that represents a high proportion of global ALK-positive NSCLC incidence.

Approved Indications for Alecnib 150 MG (Alectinib)

Alecnib 150 MG (Alectinib) is indicated across two clinically validated settings in ALK-positive NSCLC, where second-generation ALK inhibition delivers superior PFS, CNS disease control, and response depth compared with first-generation ALK-TKI crizotinib or systemic chemotherapy:

Key Clinical Benefits of Alecnib 150 MG (Alectinib)

How to Take Alecnib 150 MG (Alectinib): Dosage Guidelines

Clinical Monitoring Requirements During Alecnib 150 MG (Alectinib) Treatment

Comprehensive clinical monitoring is mandatory before and throughout the course of Alecnib (Alectinib) treatment. Before initiating therapy, oncologists must complete liver function tests (ALT, AST, alkaline phosphatase, bilirubin), creatine phosphokinase (CPK), complete blood count (CBC), and baseline cardiac rate assessment by clinical examination or ECG. Liver function tests are the highest-priority ongoing laboratory assessment: ALT, AST, and bilirubin must be evaluated every 2 weeks during the first 3 months of treatment and then monthly thereafter, with additional testing whenever hepatotoxicity symptoms such as jaundice, dark urine, abdominal pain, or fatigue develop. Grade 2 ALT or AST elevation greater than 3 times the upper limit of normal (ULN) with concurrent bilirubin greater than 2 times ULN requires immediate permanent treatment discontinuation. Grade 3 ALT or AST elevation (greater than 5 times ULN) without elevated bilirubin requires treatment interruption and dose reduction to 450 mg twice daily upon recovery to grade 1 or below; grade 4 hepatotoxicity requires permanent discontinuation.

Interstitial lung disease (ILD) and pneumonitis occurred in 3.3% of alectinib-treated patients in the ALEX trial, with 0.9% grade 3 or higher events. Any new or worsening respiratory symptoms including dyspnea, cough, or fever during alectinib therapy must prompt immediate radiographic evaluation and treatment interruption; grade 2 or higher confirmed ILD/pneumonitis requires permanent discontinuation. Bradycardia is reported in approximately 19% of alectinib-treated patients, predominantly asymptomatic; heart rate must be assessed at each clinical visit. Alectinib must be permanently discontinued for life-threatening symptomatic bradycardia not attributable to an identifiable concomitant medication. Creatine phosphokinase (CPK) elevation occurred in up to 43% of patients in ALEX, predominantly grade 1 to 2; CPK must be measured monthly and whenever muscle pain, tenderness, or weakness is reported. Grade 4 CPK elevation, or any grade CPK elevation accompanied by severe muscle symptoms, requires permanent treatment discontinuation. Photosensitivity reactions have been reported with alectinib: patients must minimize direct sun exposure, wear protective clothing, and apply broad-spectrum SPF 50 or higher sunscreen daily throughout treatment, and must avoid sunlamps and tanning beds entirely. On radiological or clinical disease progression during alectinib therapy, repeat tumor biopsy or liquid biopsy by next-generation sequencing (NGS) is strongly recommended to identify specific on-target ALK resistance mutations (G1202R, I1171T/N, V1180L) and off-target resistance mechanisms, which determine eligibility for lorlatinib, a third-generation ALK inhibitor active against alectinib-resistance mutations including G1202R.

Drug Interactions and Important Safety Information for Alecnib 150 MG (Alectinib)

Alectinib is primarily metabolized by CYP3A4, and its active metabolite M4 is also a CYP3A4 substrate. Strong CYP3A4 inhibitors, including itraconazole, ketoconazole, clarithromycin, voriconazole, ritonavir, and grapefruit and grapefruit juice, increase alectinib and M4 plasma exposure and may amplify alectinib-related adverse reactions including hepatotoxicity, bradycardia, and CPK elevation. Avoid concurrent use of strong CYP3A4 inhibitors during alectinib therapy wherever clinically possible; if co-administration cannot be avoided, monitor closely for signs of alectinib toxicity intensification. Strong CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort, substantially reduce alectinib and M4 plasma exposure, potentially compromising therapeutic efficacy against ALK-positive NSCLC tumors; these agents should be avoided throughout alectinib treatment, and an alternative co-medication with lower CYP3A4-inducing potential should be selected wherever possible.

Alectinib and its active metabolite M4 are inhibitors of BCRP (breast cancer resistance protein) and may increase the plasma concentrations of BCRP substrates, including rosuvastatin and other statins; monitor patients for signs of rosuvastatin-associated myopathy or rhabdomyolysis if co-administration is required and use the lowest effective statin dose. Alectinib is also a P-glycoprotein (P-gp) inhibitor and may increase the exposure of P-gp substrates with a narrow therapeutic index, such as digoxin, colchicine, and certain immunosuppressants; monitor closely for P-gp substrate toxicity. Because alectinib causes bradycardia, concurrent use of other heart-rate-reducing agents, including beta-blockers, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), digoxin, and ivabradine, compounds the bradycardic effect and requires close heart rate monitoring with dose modification of the contributing agent if symptomatic bradycardia develops. Women of reproductive potential must use highly effective contraception during alectinib treatment and for 3 months after the final dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose. Breastfeeding must be discontinued during alectinib treatment and for 1 week after the final dose due to potential risks to the nursing infant. Patients must disclose all current medications, herbal preparations, and dietary supplements to their oncologist before starting Alecnib therapy.

Side Effects and Precautions of Alecnib 150 MG (Alectinib)

Who Should Use Alecnib 150 MG (Alectinib)?

Alecnib 150 MG (Alectinib) is prescribed for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by a validated ALK diagnostic assay, across two approved clinical settings: as first-line therapy replacing crizotinib as the international standard of care, supported by the ALEX and ALESIA phase III trial datasets; and as second-line therapy for patients who progressed on or became intolerant to crizotinib, supported by the ALUR phase III trial. ALK positivity must be confirmed by a validated companion diagnostic assay such as the Ventana ALK (D5F3) CDx immunohistochemistry (IHC) assay (FDA-approved), fluorescence in situ hybridization (FISH), or comprehensive next-generation sequencing (NGS) of tumor tissue or plasma before initiating alectinib therapy. Alectinib is particularly the preferred treatment option for patients with CNS metastases at diagnosis or at high risk of CNS progression, given its documented blood-brain barrier penetration and intracranial ORR of 81% in the ALEX trial. ALK-positive NSCLC accounts for approximately 3 to 5% of all NSCLC diagnoses and disproportionately affects younger patients, never-smokers or light smokers, and those with adenocarcinoma histology, making comprehensive molecular profiling of all newly diagnosed advanced NSCLC patients a prerequisite for identifying ALK-positive cases and ensuring optimal therapy selection. Alecnib is prescribed exclusively by medical oncologists or thoracic oncologists with expertise in precision oncology and ALK-TKI therapy for lung cancer. For institutions and distributors requiring a comprehensive range of targeted lung cancer therapies, immunotherapies, and supportive oncology agents, Mediaid Pharmacy’s oncology specialty medicines portfolio provides a complete range of precision cancer treatments sourced from verified international manufacturers.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Alecnib 150 MG (Alectinib)

Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted therapy medications, supplying Alecnib 150 MG (Alectinib) with reliable worldwide shipping to South Asia, the Middle East, Africa, Southeast Asia, Europe, and beyond. Alecnib 150 MG is registered for export only and is supplied in a 56-tablet pack, supporting the dosing cycle for patients on alectinib therapy. Our specialist team provides complete order support including pricing quotations, stock availability confirmation, regulatory and import documentation, and end-to-end international delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for all inquiries regarding Alecnib 150 MG (Alectinib) availability, pricing, and international delivery to your country. Buyers who require additional targeted oncology medicines within a single consignment can review the full oncology medicine collection at Mediaid Pharmacy before requesting a combined quotation.

Why Choose Alecnib 150 MG (Alectinib) from Mediaid Pharmacy?

Alecnib 150 MG (Alectinib) gives oncology teams a clinically proven, second-generation ALK-TKI backed by the landmark ALEX, ALESIA, and ALUR trial datasets: a median first-line PFS of 34.8 months (versus 10.9 months for crizotinib), an intracranial ORR of 81% in patients with baseline CNS disease (versus 50% for crizotinib), a CNS progression rate of only 12% (versus 45% for crizotinib), a 5-year PFS rate of 19% (versus 0% for crizotinib), and a post-crizotinib ORR of 37.5% (versus 2.9% for chemotherapy) that is unmatched by first-generation ALK inhibitors or chemotherapy in this setting. The 150 mg tablet strength in a 56-tablet pack enables oncologists to deliver the full 600 mg twice-daily standard dose (four 150 mg tablets twice daily) and execute the complete two-step dose reduction protocol to 450 mg and then 300 mg twice daily without tablet manipulation, compounding, or dose approximation. Mediaid Pharmacy supplies Alecnib 150 MG with full product specifications, direct oncology specialist support, and worldwide shipping. Every order is initiated through a prescription-based inquiry to ensure supply is aligned with verified clinical need. To source additional ALK-pathway agents, EGFR inhibitors, immunotherapies, or other targeted cancer therapies for a comprehensive NSCLC treatment program, visit the Mediaid Pharmacy oncology medicines section, then contact our team for a personalized quotation.

Frequently Asked Questions About Alecnib 150 MG (Alectinib)